P2RX3 and diabetic neuropathy: At present, four P2X3 and P2X2/3R allosteric antagonists are under evaluation in different phases of clinical trials for the treatment of patients suffering of overactive bladder, diabetic neuropathies, endometriosis, and refractory chronic cough.